Structural abnormalities in the long arm of chromosome 3 have been detected in 7-10% of patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes. Patients with the 3q21q26 syndrome, an AML or myelodysplastic syndromes with chromosomal translocations or inversions that involve bands 3q21 and 3q26.2, exhibit specific clinical features including elevated platelet counts, hyperplasia and dysplasia of megakaryocytes, association with -7 or 7q-, refractoriness to therapy and poor prognosis. 1, 2 In these cases, the EVI1 (ecotropic virus integration site-1) gene, which maps to 3q26.2, is typically activated. 3 The late appearance of a Philadelphia (Ph) chromosome in AML has been only anecdotally reported. 4 We report a patient with AML and 3q21q26 syndrome who developed a late-appearing Ph chromosome shortly after induction chemotherapy with cytarabine and idarubicin.
A 52-year-old man underwent bone marrow aspiration and biopsy in July 2006 to evaluate worsening anemia over the previous 4 months and a peripheral white blood cell (WBC) count of 4.6 Â 10 9 l À1 with 5% blasts. A diagnosis of AML-M2 (FrenchFAmerican-British [FAB] classification) was made, with 59% myeloid blasts. The patient received therapy with intravenous daunorubicin and cytarabine on a 7 þ 3 regimen for two cycles. After a follow-up, bone marrow analysis demonstrated 13% blasts, he received gemtuzumab ozogamicin (Myelotarg) for two cycles. Subsequent bone marrow aspiration showed 84% blasts. The patient presented to our institution in December of 2006 seeking treatment options for refractory AML. At presentation his peripheral WBC count was 24.8 Â 10 9 l
À1
, with 74% blasts. Conventional cytogenetic analysis revealed 45,XY,inv(3)(q21q26.2),-7 in all 20 metaphases analyzed. Fluorescence in situ hybridization (FISH) for BCR/ABL1 rearrangement was negative. Four weeks after receiving one course of high-dose cytarabine and 5-azacytidine, bone marrow aspiration showed 81% blasts. In addition to the previously described cytogenetic abnormalities, one of 20 metaphases showed the t(9;22)(q34;q11.2) and FISH study for BCR/ABL1 rearrangement was positive in 2.5% of the interphases. The patient was then treated on a phase I study with triciribine, a novel tricyclic nucleoside that selectively inhibits the cellular phosphorylation and activation of AKT. Again there was no response to treatment, with 90% blasts in the bone marrow. Cytogenetic analysis demonstrated a predominant clone that showed inv(3) and -7 in 16 of 20 metaphases, and a smaller subpopulation that also showed t(9;22)(q34;q11.2) (Figure 1a) . Dual-color FISH analysis to detect EVI1 gene rearrangement showed a pattern that was consistent with EVI1 rearrangement/inv(3q) in 160 out of 200 interphases (Figure 1b) . 5 Flow cytometry demonstrated the myeloid nature of the blastic cells, which were positive for CD13, HLADR, CD33, CD34, CD117 and negative for CD3, CD20, CD38 and CD10. Mutations of the FLT3, NRAS and KRAS genes were not detected. Despite therapy with SJG-136 (a pyrrolobenzodiazepine dimer that binds the minor groove of DNA), followed by idarubicin and oral suberoylanilide hydroxamic acid (SAHA), the blast counts remained essentially unchanged in the peripheral blood and bone marrow. The patient also developed involvement of his cerebrospinal fluid that was unresponsive to intrathecal cytarabine. His course was complicated further by Gram-negative sepsis, atrial fibrillation and congestive heart failure. The patient chose palliative therapy and expired 9 months after presentation.
The proto-oncogene EVI1 encodes a zinc-finger transcription factor initially identified as a common site of retroviral integration in murine myeloid leukemias. Its expression is normally confined to non-hematopoietic cells. 3 Transcriptional activation of EVI1 in the 3q21q26 syndrome results in differentiation blockade of early myeloid cells in response to G-CSF. 6 EVI1 has been implicated in the self-renewal and transformation of hematopoietic stem cells (HSCs), and the pathogenesis of highly aggressive forms of AML and myelodysplastic syndromes. [7] [8] [9] As in the present case, rearrangements of 3q21q26.2 are commonly accompanied by additional recurring chromosomal abnormalities, such as -7, 7q-, or -5. Several studies suggest that inappropriate expression of EVI1 in immature hematopoietic cells interferes with erythroid and granulocytic development. 10 Although 3q21q26.2 rearrangements have been described in patients with CML in blast crisis, 11 the development of a lateappearing Ph chromosome in patients with AML and the 3q21q26 syndrome is extremely rare. Recent reports indicate that patients with high EVI1 mRNA levels before treatment respond well to the combination of arsenic trioxide and thalidomide. 12 This finding is consistent with the observation that forced EVI1 expression in murine bone marrow progenitors results in increased sensitivity to the growth inhibitory effects of arsenic trioxide. 8 In our case, another approach might have been to target the Ph þ clone with ABL1 tyrosine kinase inhibitors. However, this strategy was likely to be of limited efficacy given the small number of leukemic cells that harbored the Ph chromosome. It is tempting to hypothesize that a more efficacious strategy would be the synchronous targeting of the PhÀ (harboring 3q21q26.2) and the Ph þ leukemic cells. The synchronous detection of 3q26.2/EVI1 gene alterations and Ph chromosome in AML, although rare, is associated with an extremely poor prognosis. The combination of arsenic trioxide and ABL kinase inhibitors provides a rational approach to these cases and warrants investigation. 
